The literature suggests that while IL-17 inhibitors share many class-wide biologic risks, their specific mechanism leads to distinct efficacy patterns (strong in HS/psoriasis but not IBD) and unique safety considerations (candidiasis risk) (18). The gene discussed is IL17A; the disease is inflammatory bowel disease.